The discovery of anti–NMDA receptor encephalitis in 2007 provided enormous boosts to immunological research in neurology and psychiatry. Anti–NMDA receptor encephalitis is associated with severe neurological and a plethora of psychiatric symptoms, including psychotic and affective phenomena (1,2). To date, several more well-characterized neuronal autoantibodies have been described (1,2). According to current international consensus criteria, a diagnosis of possible autoimmune encephalitis (AE) should be considered in the presence of a subacute neuropsychiatric syndrome (with severe working memory deficits, an altered mental state, or psychiatric symptoms) in combination with at least one further organic sign, such as inflammatory cerebrospinal fluid (CSF) changes with an increased white blood cell (WBC) count, suspicious magnetic resonance imaging (MRI) changes, epileptic seizures, or focal neurological signs (2).